公开(公告)号：US20250026839A1

公开(公告)日：2025-01-23

申请号：US18707922

申请日：2022-11-09

Applicant: OSE IMMUNOTHERAPEUTICS ,  NANTES UNIVERSITE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Inventor： Vanessa Gauttier ,  Caroline Mary ,  Nicolas Poirier ,  Emmanuelle Wilhelm ,  Géraldine Teppaz ,  Elise Chiffoleau

IPC: C07K16/28 ,  C07K14/47

Abstract: The invention relates to the use of compounds that reduce the signaling pathway induced by CLEC-1/TRIM21 interaction, in particular compounds that antagonize the interaction, in particular the binding between CLEC-1 and TRIM21, the use of the identified ligand TRIM21 for designing treatment in a patient, in the identification of cells susceptible to interact with cells expressing CLEC-1, and their uses in therapy.

公开(公告)号：US20240352135A1

公开(公告)日：2024-10-24

申请号：US18600697

申请日：2024-03-09

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： Nicolas POIRIER ,  Caroline MARY ,  Bernard VANHOVE ,  Virginie THEPENIER

IPC: C07K16/28 ,  C07K16/24

CPC classification number: C07K16/2866 ,  C07K16/244 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

公开(公告)号：US11713356B2

公开(公告)日：2023-08-01

申请号：US16754285

申请日：2018-10-15

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： Nicolas Poirier ,  Caroline Mary ,  Bernard Vanhove

IPC: A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  C07K16/28 ,  A61K35/17 ,  A61K45/06

CPC classification number: C07K16/2896 ,  A61K35/17 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  C07K16/2878 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides new modified anti-SIRPa antibodies linked to an immunotherapeutic agent which are bifunctional and able to specifically enhance the immune response and uses thereof.

公开(公告)号：US11696936B2

公开(公告)日：2023-07-11

申请号：US16767144

申请日：2017-11-27

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： Dominique Costantini

IPC: A61K38/10 ,  A61K38/08 ,  A61P35/00 ,  A61K45/06

CPC classification number: A61K38/10 ,  A61K38/08 ,  A61P35/00 ,  A61K45/06

Abstract: The present invention relates to improved treatment of cancer, in particular to a treatment with a composition of CTL peptides for patients after a treatment with an immune checkpoint inhibitor.

公开(公告)号：US20230087125A1

公开(公告)日：2023-03-23

申请号：US18049876

申请日：2022-10-26

Applicant: Memorial Sloan-Kettering Cancer Center ,  Ose Immunotherapeutics

Inventor： Prasad S. Adusumilli ,  Nicolas Poirier

IPC: A61K35/17 ,  A61P35/00

Abstract: The presently disclosed subject matter provides methods for treating neoplasia using cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) that specifically targets CD127.

公开(公告)号：US20220389104A1

公开(公告)日：2022-12-08

申请号：US17334158

申请日：2021-05-28

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： Nicolas POIRIER ,  Irène BACCELLI ,  Caroline MARY ,  Sabrina PENGAM

IPC: C07K16/28 ,  A61P35/02 ,  A61K31/573

Abstract: The invention pertains to the field of immunotherapy. The present invention provides a new use of anti-CD127 agent, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer.
The invention relates to a method for treating a patient having a CD127-positive cancer, in particular a CD127-positive leukemia, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and that does not have Antibody Dependent Cytotoxic Activity (ADCC), in particular on immune cells, more particularly on T cells.

公开(公告)号：US11365257B2

公开(公告)日：2022-06-21

申请号：US16343757

申请日：2017-10-20

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE NANTES ,  OSE IMMUNOTHERAPEUTICS

Inventor： Elise Chiffoleau ,  Géraldine Teppaz ,  Nicolas Poirier ,  Bernard Vanhove ,  Vanessa Gauttier

IPC: A61P35/00 ,  C07K14/47 ,  C12N15/115 ,  C07K16/28

Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.

公开(公告)号：US20220025050A1

公开(公告)日：2022-01-27

申请号：US17414968

申请日：2019-12-17

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： NICOLAS POIRIER ,  CAROLINE MARY ,  VIRGINIE THEPENIER ,  AURORE MORELLO

IPC: C07K16/28 ,  C07K14/54 ,  C12N15/63

Abstract: The present invention provides a bifunctional molecule comprising a humanized anti-hPD-1 antibody or antigen binding fragment thereof linked to an immunotherapeutic agent able to specifically enhance the immune response and uses thereof.

公开(公告)号：US20190382483A1

公开(公告)日：2019-12-19

申请号：US16485697

申请日：2018-02-15

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： NICOLAS POIRIER ,  CAROLINE MARY ,  VANESSA GAUTTIER ,  Virginie THEPENIER ,  Sabrina PENGAM ,  BERNARD VANHOVE

IPC: C07K16/28 ,  G01N33/68 ,  A61P37/06

Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.

公开(公告)号：US20180312600A1

公开(公告)日：2018-11-01

申请号：US15769689

申请日：2016-10-21

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： Nicolas Poirier ,  Bernard Vanhove ,  Vanessa Gauttier

IPC: C07K16/28 ,  C12N5/0786 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2827 ,  C07K16/2878 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/31

Abstract: The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.